ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Health Technology

Hisamitsu Pharmaceutical Co., Inc.

Business Summary

Hisamitsu Pharmaceutical Co., Inc. engages in the research, development, manufacture, and sale of pharmaceuticals and related products. Its products are sold under Salonpas, Salonsip, Mohrus, ByeBye-Fever, and Keplat brands. It also provides ethical pharmaceuticals, over- the-counter drugs, medical devices, health supplements, and topical analgesic products. The company was founded by Nihei Hisamitsu in 1847 and is headquartered in Tosu, Japan.

Financial Highlights

Feb 2020 JPYUSD
Revenue140,992M1,293.38M
Gross Profit87,604M803.63M
Operating income22,729M208.50M
Income before tax26,155M239.93M
Net income18,694M171.48M
EBITDA26,980M247.50M
Diluted EPS227.292.08
Dividends Per Share830.76
Total Assets307,401M2,849.86M
Total liabilities56,652M525.21M
Total equity249,276M2,310.99M
Operating cash flow27,395M251.30M
Currency in JPYCurrency in USD

Historical Data

 Feb 2016Feb 2017Feb 2018Feb 2019Feb 2020
Revenue 161,852M 145,925M 147,870M 143,408M 140,992M
Gross Profit 102,465M 91,840M 92,182M 88,681M 87,604M
Operating income 27,730M 26,306M 26,346M 22,280M 22,729M
Income before tax 27,922M 29,984M 27,694M 25,673M 26,155M
Net income 17,784M 20,395M 19,120M 19,204M 18,694M
EBITDA 36,275M 33,674M 32,351M 28,022M 26,980M
Diluted EPS 208.76 241.14 228.34 229.85 227.29
Dividends Per Share 81 81.50 82 82.50 83
Total Assets 284,954M 278,820M 299,913M 295,786M 307,401M
Total liabilities 58,859M 49,611M 54,681M 47,154M 56,652M
Total equity 225,095M 228,108M 244,000M 247,334M 249,276M
Operating cash flow 30,923M 19,910M 30,453M 15,772M 27,395M
 Feb 2016Feb 2017Feb 2018Feb 2019Feb 2020
Revenue 1,340.64M 1,347.79M 1,327.30M 1,298.05M 1,293.38M
Gross Profit 848.73M 848.25M 827.44M 802.69M 803.63M
Operating income 229.69M 242.96M 236.48M 201.66M 208.50M
Income before tax 231.28M 276.93M 248.58M 232.37M 239.93M
Net income 147.30M 188.37M 171.62M 173.82M 171.48M
EBITDA 300.47M 311.02M 290.38M 253.63M 247.50M
Diluted EPS 1.72 2.22 2.04 2.08 2.08
Dividends Per Share 0.67 0.75 0.73 0.74 0.76
Total Assets 2,524.50M 2,492.02M 2,810.67M 2,657.07M 2,849.86M
Total liabilities 521.45M 443.41M 512.45M 423.58M 525.21M
Total equity 1,994.19M 2,038.77M 2,286.67M 2,221.82M 2,310.99M
Operating cash flow 256.14M 183.89M 273.35M 142.75M 251.30M

Valuation Measures

Feb 2020
PER21.24
ROA6.19%
ROE7.52%
Operating margin16.12%
Profit margin13.25%

Key executives

  • President & Representative Director: Kazuhide Nakatomi
  • Director, Executive Officer, Manager-Finance & IR: Shinichiro Takao
  • Senior Executive Officer, GM-R&D: Takaaki Terahara
  • Director, Manager-Legal Affairs & Head-Compliance: Nobuo Tsutsumi
  • MD, Executive Officer & Head-Operations: Tetsuo Akiyama

Shareholders

  • Government of Japan (5.7%)
  • Nishi Nippon City Bank Pension Fund (5.1%)
  • Bank of Tokyo Mitsubishi UFJ Pension Fund (5.0%)
  • Nippon Life Insurance Co. (4.5%)
  • Fukuoka Financial Group, Inc. (4.2%)
  • Hisamitsu Pharmaceutical Co., Inc. (3.9%)
  • The Bank of Saga Ltd. (2.7%)
  • Hisamitsu Pharmaceutical Business Association (2.7%)
  • Sumitomo Mitsui Banking Pension Fund (2.4%)
  • The Vanguard Group, Inc. (2.3%)

Contact Details

Related Companies

  • Hisamitsu Pharmaceutical (Hong Kong) Co., Ltd.
  • Hisamitsu Pharmaceutical (China) Co., Ltd.
  • Nakatomi Memorial Foundation
  • Hisamitsu Pharmaceutical Co., Ltd
  • Hisamitsu Farmaceutica do Brasil Ltda.
  • Hisamitsu Vietnam Pharmaceutical Co. Ltd.
  • PT Hisamitsu Pharma Indonesia
  • Hisamitsu UK Ltd.
  • Hisamitsu Pharmaceutical Business Association
  • Hisamitsu Pharmaceutical Tech Consulting (Beijing) Co. Ltd.
  • CRCC Media Co., Ltd.
  • Hisamitsu America, Inc.
  • Saga City Vision KK
  • Hisamitsu US, Inc.
  • SSP Co. Ltd. /Ethical Medicine Division/
  • Noven Pharmaceuticals, Inc.

Competitors

  • DURECT Corporation
  • KemPharm, Inc.
  • Icure Pharmaceutical Inc.
  • Zosano Pharma Corp.
Last Updated on 20 Nov, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more